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Abstract
Immune cytopenias are mediated by auto-antibodies
produced by B-lymphocytes. Conventional treatment of
immune-mediated haematological disorders includes
immunosuppression with steroids and other immune
modulating therapies and in some refractory cases,
splenectomy. Response rates to conventional and second-line
agents are variable and a proportion of patients require
lifelong immunosuppression to maintain the disease in
remission. Rituximab, an anti- CD 20 monoclonal antibody
has gained widespread acceptance in the management of B-
cell malignancies. Additionally, it has been used to treat the
disorders associated with autoantibody production. We report
herein the successful use of Rituximab in the treatment of two
patients with autoimmune cytopenias one had Evan's
syndrome and other had refractory immune thrombocytopenic
purpura. Both of these patients are still in remission at 16 and
25 months following treatment. 
Introduction
Autoantibodies directed against blood cells give rise to
various haematological disorders. Immune thrombocytopenic
purpura (ITP) is mediated by auto-antibodies against platelets
leading to thrombocytopenia and mucocutaneous bleeding1
while Evans syndrome is a rare disorder characterized by
thrombocytopenia and auto-immune haemolytic anaemia
(AIHA).2 Commonly employed therapies for autoimmune
cytopenias are usually corticosteroids and/or intravenous
immunoglobulin. Other options like azathioprine, cyclosporine,
vincristine, danazol or combinations of these agents are
frequently used as second-line agents while splenectomy is
indicated in relapsed or refractory cases.3 However, current
treatment regimens tend to be relatively non-selective in their
mechanism of action and aim for generalized
immunosuppression and may be associated with systemic
toxicities.2 Rituximab is a monoclonal antibody directed against
CD-20 antigen present on B-lymphocytes. Although, Rituximab
has been approved for various B-cell lymphoproliferative
diseases, there has been growing experience in its use in other
autoimmune diseases.4 In this report, we describe, cases of
Evans syndrome and refractory immune thrombocytopenic
purpura successfully treated with Rituximab.
Case 1:
A 14-year-old girl presented with history of fever and
menorrhagia. Physical examination revealed mild jaundice
and petechial rash on lower extremities. Past history was
significant for acute ITP six-months back that remitted after a
course of steroids. At presentation, her blood count showed
haemoglobin of 9.1 g/dL, platelets 25 x 109/L, and white cells
4.5 x 109/L. The peripheral blood film showed polychromasia,
nucleated red cells and marked spherocytosis. The
polyspecific direct anti globulin test was strongly positive and
monospecific DAT was positive for IgG. Clinical chemistry
revealed a raised indirect bilirubin 4.2 mg/dl, elevated lactate
dehydrogenase 2880 IU/L and a raised positive titer of anti ds-
DNA 14.8 IU/ml. The results of ANA (antinuclear antibody)
were indeterminate. However, the diagnosis of SLE (systemic
lupus erythematosus) was excluded on the basis of absence of
systemic disease as well as a negative panel of extractable
nuclear antibodies that includes anti-Ro, anti-RNP, anti-La
and anti-Sm. There was no evidence of lymphoproliferative
disorder either on CT scanning or on bone marrow biopsy. She
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was diagnosed as Evans Syndrome and therapy was
commenced with oral prednisolone at a dose of 1 mg/kg/day.
After two weeks, the patient attained a partial response with
platelet count of 58,000, however, a significant rise in
haemoglobin was not seen. Subsequently, gradually tapering
doses of steroids dropped her platelet counts and
haemoglobin. No significant improvement was seen after the
addition of second line agent, azathioprine. She persistently
remained thrombocytopenic with platelet counts fluctuating
between 5-10 x 109/L and she also required pack red cell
transfusion on multiple occasions for correction of anaemia.
Considering the refractory nature of the disease, she was given
Rituximab at a dose of 375 mg/m2 weekly for six consecutive
weeks. After the first dose of rituximab, her haemoglobin and
platelet count improved significantly from the baseline
(haemoglobin 10.3 g/dL and platelets 79 x 109/L) and LDH
and bilirubin also returned towards normalization enabling
both cessation of transfusion support and weaning of the
prednisolone dosage. After completion of sixth dose of
Rituximab she attained haemoglobin of 11.1 g/dl and platelets
of 132 x 109/L. Her prednisolone and azathioprine were
tapered and stopped within 3 months. Currently at 16-months
follow-up, her haemoglobin is 11.9 g/L and platelets 201 x
109/L with otherwise, normal bilirubin, LDH, reticulocyte
count and a negative DAT
Case 2:
A 21-year-old girl presented with complaints of gum
bleeding and petechial rashes. General physical and systemic
examination was unremarkable except for purpuric rashes on
the upper and lower limbs. She was a known case of chronic
refractory ITP and was diagnosed in 2000. She has received
multiple drugs in the past which included oral and intravenous
steroids, azathioprine, intravenous immune globulin and
cyclophosphamide. Splenectomy was done in 2001
considering the refractory nature of the disease. This time at
presentation her platelet count was 3 x 109/L; other CBC
parameters were within normal limits. Her direct antiglobulin
test and ANA profile was negative. Considering her past
history, she was offered a trial of Rituximab, and was started
on weekly Rituximab at a dose of 375mg/m2 for four
consecutive weeks. Upon, completion of 4th dose of weekly
Rituximab, her platelet count normalized to 235 x 109/L.
Currently on 25-months follow-up she is maintaining a
normal platelet count.
Discussion
The use of Rituximab is currently limited in
autoimmune haematological disorders, partly because it is not
an approved indication for the usage and also because of the
cost as well. However, based on the encouraging results from
various recent studies Rituximab has been successfully used in
an off-label setting in a wide range of clinical disorders.2
Previous studies have reported a variable response to
the use of Rituximab in Evans syndrome, as some have
reported a success5 while others have noted no appreciable
response.6 The complete remission rate with the use of
Rituximab in Evans syndrome and ITP has been reported
around 40% and 75% respectively, with no difference of
responses seen between splenectomized and non-
splenectomized patients.7,8 The patients who responded to
Rituximab and achieved complete remission have shown a
median duration of remission of about 73 weeks.9,10
In this report, both patients met the criteria for a
response as defined by the normalization of a rise in
haemoglobin of at least 1.5 g/L from baseline and an absolute
haemoglobin level above 10 gm/dL and platelet count >50
x109/L at least 1 month after completion of therapy.7 The cases
reported here add to the relatively sparse data on the use of
Rituximab in Evans syndrome and immune thrombocytopenic
purpura and based on the growing literature and experience
with Rituximab, it should now be considered as an option in
refractory auto-immune cytopenias. 
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